Creative Biolabs provides customized support across key stages of lipid-based therapeutic development, helping researchers optimize delivery systems for different types of therapeutic payloads, ...
Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing PIKTOR, an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway, will present translational data ...
Influence of single agent gemcitabine (GEM) schedule on the pattern of response and toxicity in patients with advanced pancreas, lung and breast carcinoma: A systematic review No significant financial ...
Developed by the Institute for Clinical Pharmacodynamics, the PK-PD Compass app provides pharmacodynamics (PD) and pharmacokinetics (PK) calculations as they pertain to antibiotics. The goal of this ...
KSP-1007 is a new bicyclic boronate-based broad-spectrum β-lactamase inhibitor that, in combination with meropenem, is under development for the treatment of infections caused by carbapenem-resistant ...